Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?
Wilson's purchase increases his total equity stake by 9% following a 62% one-year stock return, signaling confidence in the oncology biotech's pipeline.